Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

ClenchFists Oct. 3 at 3:51 PM

$RANI She wanna hop in a Rani.

0 · Reply

Fishbonee Oct. 3 at 2:44 PM

$RANI

0 · Reply

highnihilism Oct. 1 at 12:33 PM

0 · Reply

S2K_TP Sep. 30 at 4:52 PM

$RANI on watch

0 · Reply

Fishbonee Sep. 30 at 1:21 AM

$RANI

0 · Reply

Fishbonee Sep. 23 at 4:50 PM

$RANI

0 · Reply

Alien1980 Sep. 19 at 7:46 PM

$RANI $AGL $ARBK $RANI $DHAI $JSPR all strong candidates to make major moves before the month is up. Add em 🤫🤫

1 · Reply

Fishbonee Sep. 19 at 2:32 PM

$RANI

0 · Reply

Letsinvest2024 Sep. 18 at 4:10 PM

$TPST it’s bio time $ETNB $CHRS $RANI

0 · Reply

Tooneyman Sep. 15 at 9:47 PM

$RANI so, how are they going to get the stock price up to $1 before December 17th ???..... Or will they ? ..... Or they won't and RANI will be delisted then .... ☹️

0 · Reply

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Jul 15, 2025, 9:00 AM EDT - 2 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 2 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

May 19, 2025, 8:00 AM EDT - 4 months ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 5 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Mar 31, 2025, 7:15 PM EDT - 6 months ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 6 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 6 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 6 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 14, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Mar 20, 2024, 7:05 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 1 year ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 8, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 24, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 10, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 5, 2023, 5:33 PM EDT - 2 years ago

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Mar 22, 2023, 6:43 PM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

Mar 16, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Jan 9, 2023, 8:30 AM EST - 2 years ago

Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

Jan 5, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

Dec 6, 2022, 4:05 PM EST - 3 years ago

Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

Nov 9, 2022, 4:05 PM EST - 3 years ago

Rani Therapeutics to Present at the Stifel Healthcare Conference

Oct 24, 2022, 8:30 AM EDT - 3 years ago

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

Sep 6, 2022, 4:05 PM EDT - 3 years ago

Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 11:47 PM EDT - 3 years ago

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

ClenchFists Oct. 3 at 3:51 PM

$RANI She wanna hop in a Rani.

0 · Reply

Fishbonee Oct. 3 at 2:44 PM

$RANI

0 · Reply

highnihilism Oct. 1 at 12:33 PM

0 · Reply

S2K_TP Sep. 30 at 4:52 PM

$RANI on watch

0 · Reply

Fishbonee Sep. 30 at 1:21 AM

$RANI

0 · Reply

Fishbonee Sep. 23 at 4:50 PM

$RANI

0 · Reply

Alien1980 Sep. 19 at 7:46 PM

$RANI $AGL $ARBK $RANI $DHAI $JSPR all strong candidates to make major moves before the month is up. Add em 🤫🤫

1 · Reply

Fishbonee Sep. 19 at 2:32 PM

$RANI

0 · Reply

Letsinvest2024 Sep. 18 at 4:10 PM

$TPST it’s bio time $ETNB $CHRS $RANI

0 · Reply

Tooneyman Sep. 15 at 9:47 PM

$RANI so, how are they going to get the stock price up to $1 before December 17th ???..... Or will they ? ..... Or they won't and RANI will be delisted then .... ☹️

0 · Reply

Robotai Sep. 12 at 9:52 AM

$RANI 📈 Follow & Subscribe Swing Trading Forecast: $RANI 📍 Current Price: $0.51 🔍 Swing Patterns: Major Upside Breakout, Bullish Trend Continuation, MACD Bullish Crossover 📊 Swing Market Structure: • Trend Regime: Strong Uptrend • Direction: Strong Bullish (80.0% confidence) • Timeframe: 3-7 days 🎯 Strong Bullish Swing Targets: • Conservative: $0.54 (+6.42%) • Primary Target: $0.56 (+10.70%) • Aggressive: $0.61 (+19.26%) • Holding Period: 3-7 days 📊 Technical Indicators: • ADX (Trend Strength): 48.6 • ATR (Volatility): $0.00 • RSI: 57.8 • MACD: Bullish 📈 Swing Signal Strength: 80.0% | Historical Patterns: 1

0 · Reply

Joepeoples77 Sep. 6 at 3:44 PM

$RANI any fear of delisting from Nasdaq since below $1 since May.

1 · Reply

S2K_TP Sep. 6 at 6:02 AM

$RANI This reclaim above $0.50 is notable. It’s a key psychological level and a pivot from recent lows. Recently raised $3M via direct offering. Their RaniPill tech — oral biologics delivery — is still early-stage but has strategic partnerships (e.g., Chugai) and promising preclinical data. If it clears $0.55 with volume, next leg could target $0.60–$0.65.

1 · Reply

Tom678 Sep. 4 at 2:12 PM

$ADVB $CCG $FTHM $RANI $STFS ADVB is rising 😎

0 · Reply

DaBullRunner Sep. 4 at 10:07 AM

$BMRA has the potential to be my next DOUBLE DIGIT ticker 🏆✅ WATCH AND LEARN JUST LIKE👇 $BRIA $BDSX $RVSN $RANI let’s get it

1 · Reply

NVDAMillionaire Sep. 4 at 5:44 AM

$RANI Really good write-up that perfectly summarizes RANI's present situation. So if you want to bring your RANI knowledge up to date or just discover RANI, this is required reading. https://beyondspx.com/quote/RANI/rani-therapeutics-the-oral-biologics-disruptor-at-a-critical-juncture-nasdaq-rani#analysis

0 · Reply

lisaparsons Sep. 3 at 1:17 AM

$RANI is this reverse splitting. Has it been confirmed guys and gals ?

0 · Reply

Letsinvest2024 Sep. 2 at 6:12 PM

$RANI WTH

0 · Reply

CallMeMyBeer Sep. 2 at 1:11 AM

$RANI reverse split and then chapter 7

0 · Reply

SPYmyQQQ Aug. 31 at 12:00 AM

🌙 EOD Recap ✅ 💊 $RANI 🗓️ Aug 30, 2025 (8pm ET) 🎯 Our Entry: $0.5700

0 · Reply

SPYmyQQQ Aug. 31 at 12:00 AM

🚨 New Signal ✅ 💊 $RANI 🗓️ Aug 30, 2025 🎯 Entry: $0.5700 🎯 Target: $0.6573 (+15.32%)

0 · Reply

SPYmyQQQ Aug. 30 at 10:11 PM

🚨 New Signal ✅ 💊 $RANI 🗓️ Aug 30, 2025 🎯 Entry: $0.5700 🎯 Target: $0.6573 (+15.32%)

0 · Reply

Market Cap	36.29M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,914.56%
Debt to Equity Ratio	-3.91

Volume	275,900
Avg Vol	528,520
Day's Range	N/A - N/A
Shares Out	71.87M
Stochastic %K	63%
Beta	-0.02
Analysts	Strong Sell
Price Target	$7.80